Remarkable immunogenicity and protective efficacy of BBV152, an inactivated SARS-CoV-2 vaccine in rhesus macaques

doi:10.21203/rs.3.rs-65715/v1

PDF

Article

Remarkable immunogenicity and protective efficacy of BBV152, an inactivated SARS-CoV-2 vaccine in rhesus macaques

https://doi.org/10.21203/rs.3.rs-65715/v1

This work is licensed under a CC BY 4.0 License

Journal Publication

published 02 Mar, 2021

Read the published version in Nature Communications →

Version 1

posted 10 Sep, 2020

You are reading this latest preprint version

The COVID-19 pandemic is a global health crisis that has severely affected mankind and posed a great challenge to the public health system of affected countries. The availability of a safe and effective vaccine is the need of the hour to overcome this crisis. Here, we have developed and assessed the protective efficacy and immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in rhesus macaques (Macaca mulata). Twenty macaques were divided into four groups of five animals each. One group was administered a placebo while three groups were immunized with three different vaccine candidates at 0 and 14 days. All the macaques were challenged with SARS-CoV-2 fourteen days after the second dose. The protective response was observed with increasing SARS-CoV-2 specific IgG and neutralizing antibody titers from 3rd-week post-immunization. Viral clearance was observed from bronchoalveolar lavage fluid, nasal swab, throat swab, and lung tissues at 7 days post-infection in the vaccinated groups. No evidence of pneumonia was observed by histopathological examination in vaccinated groups, unlike the placebo group which showed features of interstitial pneumonia and localization of viral antigen in the alveolar epithelium and macrophages by immunohistochemistry. Data from this study substantiate the immunogenicity of the vaccine candidates and BBV152 is being evaluated in Phase I clinical trials in India (NCT04471519).

General Microbiology

Vaccine Development

SARS-CoV-2

vaccine

BBV152

immunogenicity

The pandemic of coronavirus disease 2019 (COVID-19) has caused an unprecedented public health burden in several countries across the globe¹. The spread of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is has infected more than 23 million people until August 2020². With all the public health measures in place, including behavioural modifications such as the use of masks, hand sanitization; pharmaceutical interventions such as antiviral drugs or safe and effective vaccines seem to be the only means of stopping this raging pandemic. With the release of the first genome sequence of SARS-CoV-2 from China on 11 January 2020, the race against the virus and time had begun for the development of an effective COVID-19 vaccine. Multiple vaccine development platforms from traditional to next-generation approaches are being used by different research groups worldwide. Purified inactivated viruses have been traditionally used in vaccine development. These inactivated vaccines are safe and effective in the prevention of diseases i.e., rabies, polio, hepatitis A, and influenza³. Here, we report the assessment of immunogenicity and protective efficacy of three formulations of a purified whole-virion inactivated SARS-CoV-2 (BBV152) vaccine candidate in the rhesus macaques.

Anti-SARS-CoV-2 IgG and neutralizing antibody response

Adverse events were not seen in animals immunized with a two-dose vaccination regimen. We evaluated anti-SARS-CoV-2 Immunoglobulin-G (IgG) antibody and neutralizing antibody (NAb) titers from the serum samples during the immunization phase (0, 12, 19, 26 and 28 days) and after SARS-CoV-2 infection (0, 1, 3, and 7) (Figure 1A). IgG levels were detectable from 3^rd-week post-immunization and were found increasing till 35th day [7 days post-infection (DPI)] (Figure 1B, 1C). Group III showed the highest IgG titer (1:25600) compared to group II and IV (1:1600-1:6400) (Figure 1D). The highest NAb titers of 1:209 to 1:5,217 were detected in group III after the SARS-CoV-2 challenge. The NAb titers for groups II and IV were (1:87.4 - 1: 3974) and (1:29.5 -1: 3403) respectively (Figure 1E, 1F). These NAb titers correlated with the IgG antibody titers (Figure 1B-F). NAb and IgG response was not detectable in the placebo group (Figure 1B-F).

Viral load in the nasal swab, throat swab and bronchoalveolar lavage fluid

Genomic RNA (gRNA) was detected from nasal swab (NS) specimens of all animals in the placebo group from 1 to 7 DPI. Viral clearance was observed in NS specimens of all the animals from the vaccinated group on 7 DPI. (Figure 2A). Subgenomic RNA (sgRNA) was detected in two of five animals at 3 DPI and one of five animals at 7 DPI of the placebo group. sgRNA was detected in the NS sample of only one animal of the vaccinated group IV on 5 DPI (Figure 2A).

Throat swab (TS) specimens of the placebo group were tested positive for gRNA at 1, 3, 5, and 7 DPI. Vaccinated groups had a detectable level of gRNA from 1 to 5 DPI with viral clearance on 7 DPI (Figure 2B). sgRNA was not detected in TS specimens of animals from either group. Bronchoalveolar lavage (BAL) fluid specimens of the animals from the placebo group were positive for gRNA from 1 to 7 DPI. In the vaccinated groups, gRNA was detected in BAL specimens until 3 DPI (Figure 2C). sgRNA was detected in BAL specimens of four out of five animals of the placebo group, while it was not detected in BAL specimens of vaccinated groups. Except for the placebo group, none of the vaccinated groups showed the presence of gRNA in lung lobes (Figure 2D). The comparisons of viral copy numbers of the NS, TS, and the BAL fluid samples of the vaccinated as compared to the placebo group were found to be statistically significant using the two-tailed Mann-Whitney test.

Viral load in the respiratory tract, lungs, and extra-pulmonary organs

On 7 DPI, animals from all the groups were sacrificed and swab samples, BAL, and various organs were collected. The animals of the placebo group at 7 DPI showed bronchopneumonic patches and consolidation in the lungs at necropsy (Figure 3A and 3B). In the placebo group, gRNA was detected in the trachea (3/5), nasopharyngeal mucosa (2/5), oropharyngeal mucosa (3/5) and nasal mucosa (1/5) specimens (Figure 3C). Four out of five animals had detectable gRNA and sgRNA in multiple lobes of the lungs (Figure 3D). Lung specimens of all animals from the vaccinated groups were found negative for gRNA and sgRNA. In the placebo group, gRNA was detected in skin, ileum, colon, gall bladder, stomach, urinary bladder, and pancreas. Only one animal from group IV showed the presence of gRNA in ileum and caecum. Heart, liver, kidney, spleen, and brain were tested negative for gRNA in all animals.

Clinico-radiological analysis

Weight loss, pyrexia, and worsening of SpO2 at room air, lethargy, reduced food and water intake, reduced self-grooming was observed in the placebo group and persisted till 7 DPI whereas these features resolved in the other group II and IV (Supplementary Table 1). The chest radiograph of the three animals in the placebo group showed infiltrates, bronchopneumonia, or lobar pneumonia which persisted till 7 DPI. Similar chest radiographic abnormalities were detected in two out of five animals in group II and IV, but resolved by 5 DPI (Extended Data Figure 1A-D). No clinical or radiographic abnormalities were detected in group III animals.

Histopathological examination and immunohistochemistry

Lung tissue showed mild to moderate interstitial pneumonia in the animals of the placebo group (Table 2) characterized by thickening of alveolar septa, hyaline membrane formation, accumulation of edematous fluid, and fibrin. Occasionally, certain foci of bronchioles showed necrosis and loss of epithelium with neutrophils and macrophage infiltration. Moderate to severe disease was present in 3 and mild disease in 2 animals of the placebo group with the involvement of four to six lung lobes. In group II, two animals had a single lobe of the lung affected (Table 3). Viral antigens were detected in the alveolar epithelium by immunohistochemistry (IHC) in the placebo group suggestive of SARS-CoV-2 infection. These findings indicate significant protection of the lungs from the vaccinated group as compared to the placebo group. Group II, III, and IV had significantly lower disease burden compared to the placebo group ( Table 3).

Virus isolation

NS, TS, BAL fluid, urine, stool, and lung tissue specimens (1 to 7 DPI) from placebo and vaccinated groups were processed for virus isolation. Cytopathic effect (CPE) was observed in TS and NS specimens of the placebo group on 1 and 3 DPI. BAL, urine, stool, and lungs specimens did not show CPE in any group. Two TS and one NS specimen of group II and IV respectively yielded virus isolation on 1 DPI.

Lymphocyte subset and cytokine/chemokine profile

Lymphocytes were found to be significantly low in the placebo (mean ± SD; 14.51±9.31, p < 0.05) compared to the vaccinated macaques (group II, mean ± SD; 31.88±15.85) on 1 DPI. The assessment based on the surface marker of gated lymphocytes from lysed whole blood showed no statistically significant difference between placebo and vaccinated groups in terms of the percentage of cells expressing CD3+, CD8+ and CD20+ till 7 DPI (Extended Data Figure 2). IL-6 was found to be of significantly higher in the placebo group (mean ± SD; 22.78±23.21, p < 0.001) compared to the group's II (mean ± SD; 2.97±4.85, p < 0.001) and III (mean ± SD; 2.65±1.98, P < 0.001). Additionally, the anti-inflammatory cytokine IL-5 was significantly higher in group II (mean ± SD; 3.14±2.41, p < 0.001) compared to the placebo group on 1 DPI. IL-8 was found significantly higher in group III on 3 DPI and 5 DPI (mean ± SD; 4653.65±3088.34, p < 0.05, mean ± SD; 4715.5±2864.15, p < 0.01) compared to the placebo group (mean ± SD; 1891.16±878.11, 3 DPI; mean ± SD; 1216.11±757.64, 5 DPI). IL-2, TNF-α, and IFN-γ were not detectable in all the animals.

A safe and effective vaccine is the need of the hour to overcome the COVID-19 pandemic. In the global race for the development of vaccines, few research groups have reported the preclinical studies of viral vector vaccines (ChAdOx1 nCoV-19 and Ad-26.COV.2.S)^{4, 5}, mRNA vaccine (mRNA-1273)⁶, DNA vaccine (INO-4800)⁷and inactivated vaccines (PiCoVacc and BBIBP-CorV)^8,9. Phase I/II clinical trial are either completed or on-going for these vaccines. Here, we report the two-dose vaccination regimen of inactivated SARS-CoV-2 vaccine candidates found to induce a strong immune response and protection of animals from the infection of SARS-CoV-2.

Neutralizing antibodies and IgG responses were observed from 3^rd-week post-immunization in vaccinated groups. IgG titer rose in an increasing pattern with the highest response in group III. The presence of gRNA in NS was observed in the placebo group until 7 DPI. Vaccinated groups had no detectable gRNA in NS on 7 DPI indicating the ability of vaccine candidates to limit upper respiratory tract viral replication, which is a key factor determining the virus transmission. gRNA and sgRNA were not detected in the BAL fluid from 5 DPI suggesting that vaccination hindered virus replication and enabled faster clearance from lower airway protecting the animals. gRNA was detected in multiple organs at necropsy in the placebo group, whereas it was found to be cleared in the vaccinated groups.

Wang et al. and colleagues reported immunogenicity of the two-dose vaccination regimen with effective NAb response in low and middle vaccine doses of inactivated SARS-CoV-2 vaccine and noted virus clearance ⁹. Similarly, Gao et al. and colleagues also reported rising titers of NAb with three dose vaccinations regimen and protection of animals by virus clearance from pharynx or lungs at 7 DPI with high vaccine dose⁸.

An elevated level of IL-6 is highly consistent in COVID-19 disease and lymphopenia may be associated with a high level of IL-6^{10, 11}. Our experimental data showed an elevated level of IL-6 in the placebo group compared to vaccinate groups (II and III) on 1 DPI, suggestive of protection against the SARS-CoV-2 infection. The transient lymphopenia in the placebo group could be suggestive of suboptimal cellular immunity in the placebo group or may be due to the recruitment of lymphocytes to the inflamed respiratory tract^{12, 13}. Furthermore, lymphopenia is specifically CD8+ T cells biased^{12, 14}, this possibly explains the elevated proportion of CD4+ T cells in the placebo group ¹². IL-5, a Th₂ cytokine, is associated with eosinophilia, and evidence of eosinophils for antiviral activity is documented^15.Our study demonstrated an elevated level of IL-5 in vaccinated group II compared to the placebo group. IL-8, a key chemokine, responsible for the recruitment of neutrophils and other immune cells was substantially high in vaccinated group III indicative of infection.

Organ viral load, interstitial pneumonia, and detection of viral antigen by IHC in lung tissue strengthen the evidence of SARS CoV-2 induced pulmonary disease in placebo animals. group III (3 µg, Adjuvant-A) animals had no clinical/radiological evidence of disease activity demonstrating significant protection from SARS-CoV-2. These findings correlate well with protection from disease demonstrated by serological, gross pathological, and HPE findings.

Altogether this study demonstrates that a two-dose vaccination regimen using 3µg dose of the vaccine candidate with adjuvant B induce a significant immune response and provide effective protection in animals challenged with SARS-CoV-2. Data from this study substantiate the immunogenicity of BBV152 which is being evaluated in Phase I clinical trials in India (NCT04471519).

Acknowledgment

Authors acknowledge the support and co-ordination from PCCF (Wildlife) and Chief Wildlife Warden, Maharashtra state, and Chief Conservator of Forests (Wildlife/Territorial), Pune Forest Division for the experimentation. Authors also acknowledge the support from Deepika Chawdhary, Mayur Mohite, Vishal Gaikwad (Engineering support), Santosh Jadhav, and laboratory team which includes Ganesh Chopade, Manjunath Holleppanavar, Mr. Rajen Lakra, Darpan Phagiwala, Chetan Patil, Chandrakant Upadhyay, Sanjay Thorat, Ratan More, Madhav Acharya, Malvika Salave, Ashwini Baghmare, Ciyona, Sapna Gawande, Poonam Bodke and Nitin Deshpande. Authors also express gratitude towards the technical team of the animal house includes Ankayya Thimanapally, Vitthal Sasane, Sunny K Athwal, Nikhil Chavan, and Swagat Deshkar.

We sincerely acknowledge Major General Arindam Chatterjee, Commandant AICTS, Pune and Major General S Hasnain, Commandant, Command Hospital (Southern Command) Pune, India, and Dr. Smita Mahale, Director, ICMR- National Institute for Research in Reproductive Health, Mumbai, Maharashtra, India for extending generous support for the study. We would also thank Havaldar Mangesh Aamre, AICTS, Pune for his excellent support in bronchoscopy.

Author’s Contribution

PDY, KME, KM, PA, NG, and BB conceived and designed the study. KME, KM, RE, VKS, and SPBS performed vaccine design and production. PDY, SK, SLM, and DRP performed the planning of the animal experiment. SK, DRP, SLM, GB, KA, SMM, BM, and MDG performed animal experimentation. PDY, ASA, GS, HK, DN, RJ, GD and DYP performed the laboratory work planning and data analysis. ASA, PDY, and RJ developed the in-house ELISA. GD, CM, HK, SP, RJ, ANK, YJ, TM, PS, SB, DM, KK, SS, RG, PG, and HD performed sample processing in the laboratory. SF, AS, MK, AK, SD, and SG assisted in animal experimentation. PDY, SK, ASA, SM, and DYP have drafted the manuscript. PDY, SP, ASA, DYP, SK, PA, NG, and BB substantively revised it. All authors reviewed the manuscript and agree to its contents.

Competing interests: None

Wang, C. et al. A novel coronavirus outbreak of global health concern.Lancet 395 (10223), 470-473.https://doi.org/10.1016/S0140-6736(20)30185-9 (2020).
World Health Organization. Coronavirus disease (COVID-19) outbreak situation. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019 (2020).
World Health Organization. Module 2: Types of vaccine and adverse reactions. https://www.who.int/vaccine_safety/initiative/tech_support/Part-2.pdf (2020).
Doremalen, N. et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature30, 1-8. https://doi.org/1101/2020.05.13.093195 (2020).
Mercado, NB. et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature30, 1-1. https://doi.org/10.1038/s41586-020-2607-z (2020).
Corbett, KS. et al.Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N Engl J Med. https://doi.org/10.1056/NEJMoa2024671 (2020).
Patel, A. et al.Intradermal-delivered DNA vaccine provides anamnestic protection in a rhesus macaque SARS-CoV-2 challenge model. bioRxiv.https://doi.org/10.1101/2020.07.28.225649 (2020).
Gao, Q. et al.Development of an inactivated vaccine candidate for SARS-CoV-2. Science. https://doi.org/10.1126/science.abc1932 (2020).
Wang, H. et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell. https://doi.org/10.1016/j.cell.2020.06.008 (2020).
Yang X, Yu Y, Xu J et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med8, 475–481. https://doi.org/10.1016/S2213-2600(20)30079-5(2020).
Mazzoni A, Salvati L, Maggi L et al. Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent. J Clin Invest. https://doi.org/10.1172/JCI138554 (2020).
Chen Z, John Wherry E. T cell responses in patients with COVID-19. Nat Rev Immunol 1–8. https://doi.org/10.1038/s41577-020-0402-6 (2020).
Chandrashekar A, Liu J, Martinot AJ, et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science 80, 4776. https://doi.org/10.1126/science.abc4776 (2020).
Surh CD, Sprent J. Homeostasis of Naive and Memory T Cells. Immunity 29, 848–862. https://doi.org/10.1016/j.immuni.2008.11.002 (2008).
Lindsley AW, Schwartz JT, Rothenberg MEet al. Eosinophil responses during COVID-19 infections and coronavirus vaccination. J Allergy Clin Immunol146, 1–7.https://doi.org/1016/j.jaci.2020.04.021 (2020).
Committee for the Purpose of Control and Supervision on Experiments on Animals. CPCSEA Guidelines for laboratory animal facility. Indian J Pharmacol 35(4). https://doi.org/10.13140/2.1.3877.2802 (2020).
Patil, DR. et al. Study of Kyasanur forest disease viremia, antibody kinetics, and virus infection in target organs of Macaca radiata. Sci Rep 10(1), 1-3. https://doi.org/1038/s41598-020-67599-x(2020).
Sapkal, G. et al. Development of indigenous IgG ELISA for the detection of anti-SARS-CoV-2 IgG. Indian J Med Res151(5), 444-449. https://doi.org/10.4103/ijmr.IJMR_2232_20 (2020).
Sarkale, P. et al. First isolation of SARS-CoV-2 from clinical samples in India. Indian J Med Res 151, 244-50.https://doi.org/10.4103/ijmr.IJMR_1029_20 (2020).
Perera, RA. et al.Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. Euro Surveill 25(16), 2000421. https://doi.org/10.2807/1560-7917 (2020).
Choudhary ML, et al. Development of in vitro transcribed RNA as positive control for laboratory diagnosis of SARS-CoV-2 in India. Indian J Med Res 151, 251-254. https://doi.org/10.4103/ijmr.IJMR_671_20 (2020).
World Health Organization. Coronavirus disease (COVID-19) technical guidance: Laboratory testing for 2019-nCoV in humans. WHO; 2020. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance (2020).
Wolfel, R. et al. Virological assessment of hospitalized patients with COVID-2019.Nature 581(7809), 465-469. https://doi.org/10.1038/s41586-020-2196-x (2020).
Kaushal, H. et al.Evaluation of cellular immunological responses in mono- and polymorphic clinical forms of post-kala-azar dermal leishmaniasis in India.Clin Exp Immunol185 (1), 50-60. https://doi.org/1111/cei.12787 (2016).
Culling, C.F.A. Handbook of Histopathological and Histochemical Techniques: Including Museum Techniques (Butterworth-Heinemann) (2013).

Ethics statement

The study was approved by the Institutional Project Review Committee, and Institutional Biosafety Committee, ICMR-National Institute of Virology (NIV), Pune. The study was recommended by the Institutional Animal Ethics Committee (Registration 43/GO/ReBi/SL/99/CPCSEA) and further approved by Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), New Delhi letter No. V11011 (13)/7/2020-CPCSEA-DADF dated 08.06.2020. The permission from the Office of Principal Chief Conservator of Forests (PCCF), Maharashtra state, and Central India was obtained for capturing of Rhesus Macaques from the wild. The research was conducted in compliance with the guidelines laid down by CPCSEA, Government of India¹⁶.

Generation of vaccine

Bharat Biotech has established biosafety level 3 (BSL3) manufacturing facilities with a highly characterized and safe vero cell manufacturing platform that were readily deployed towards process development and large-scale manufacturing. Vero CCL-81 cells were initially grown in tissue culture flasks and cell stacks using Dulbecco's Modified Eagle Medium (DMEM) (Sigma-Aldrich, India) containing 5-10% newborn calf serum (NBCS). Virus propagation was done in bioreactors at the temperature of 36 ± 1°C and was harvested at 36-72 h post-infection and supernatants were collected, clarified, and aliquoted. The virus was inactivated with ß-propiolactone at a ratio of 1:2000 – 1:4000 at 2-8°C for 24-32 h. It was further purified by column chromatography and concentrated using a tangential flow filtration system. A total of three vaccine formulations were prepared, namely BBV152A (3µg+alum+ imidazoquinoline), BBV152B (6µg+alum+ imidazoquinoline), and BBV152C (6µg+alum). Imidazoquinoline are TLR7 / TLR8 agonists, which are highly immunostimulatory in nature.

Study design and experiments on rhesus macaques

Rhesus macaques (Macaca mulatta) were housed in individual cages at the animal facility of ICMR-NIV, Pune. The animals were maintained on commercial pelleted feed, fruits, vegetables, and ad-libitum potable drinking water with a 12h/12h dark/light cycle. All the animals were clinically evaluated for skin/systemic disorders, hemoglobin, total leukocyte count, differential leukocyte count, platelet count, packed cell volume, biochemical parameters (AST, ALT, bilirubin, serum proteins, alkaline phosphatase, LDH, BUN, creatinine, cholesterol, triglycerides, sodium, potassium, glucose), abdominal ultrasonography, chest X-ray, tuberculin test and were found fit for the study. Animals were screened for Kyasanur forest disease virus and SARS-CoV-2 and IgG antibodies and found to be negative^{17, 18}. Biomedic data systems temperature transponder was implanted in the interscapular region subcutaneously for monitoring of body temperature during the study.

Twenty adult animals aged 3 - 12 years were divided into 4 groups of five animals (3 M, 2 F) each viz. the placebo (group I), group II, III, and IV. The placebo group was administered Phosphate buffer saline (PBS), group II, III, and IV were immunized with formulations of purified inactivated SARS-CoV-2 vaccine candidate 6μg+Adjuvant-A(BBV152C), 3μg+Adjuvant-B (BBV152A), and 6μg+Adjuvant-B (BBV152B) respectively. Animals were administered with two doses of vaccine/placebo on days 0 and 14 respectively intramuscularly in the deltoid region. Blood samples were collected on 0, 12, 19, 26, and 28 days for assessing the anti-SARS IgG antibody and NAb titers (Figure 1A).

After completion of twenty eight-days of immunization, animals were shifted to animal biosafety level–4 facility. Animals were challenged with 1 ml of SARS-CoV-2 (P-3, NIV-2020770, TCID50 10⁶^.⁵/ml)¹⁹ intratracheally and 0.25 ml in each nostril. Animals were monitored twice daily and clinical scoring was performed based on parameters as listed in Supplementary Table 3. Clinical examination was done on 0, 1, 3, 5, and 7 DPI along with body temperature, body weight, pulse rate, and oxygen saturation at room air (Supplementary Table 3). NS, TS, rectal swab, chest X-ray, blood specimens, and BAL fluid were collected on 0, 1, 3, 5, and 7 DPI. BAL fluid collection was performed using a flexible pediatric bronchoscope (Pentax Medical India Private Limited) under general anesthesia. The bronchoscope was inserted into the trachea and was guided through bronchus past the 3rd bifurcation; 5 ml of normal saline was instilled and aspirated from the lower/middle lobes of the lungs bilaterally. On 7 DPI, a detailed bronchoscopy and BAL fluid collection from lobes of the lungs bilaterally were performed.

During necropsy, the following organs; brain, nasal mucosa, tonsil, nasopharynx, oropharynx, cervical lymph node, trachea, lungs, mediastinal lymph node, heart, spleen, liver, kidneys, urinary bladder, gastrointestinal tract and skin along with underlying deltoid muscle from the immunization site and cerebrospinal fluid (CSF) were collected.

Enzyme-linked immunosorbent assay for detection of anti-SARS-CoV-2 IgG antibody

Immunoplates (Maxisorp, Nunc) were coated with 100 μL/well of SARS CoV-2 antigen overnight at 4°C in the carbonate buffer. Subsequently, wells were blocked with liquid plate sealer (CANDOR Bioscience GmbH, Germany) for two hours at room temperature (25-30°C). One hundred μL of diluted rhesus macaque serum samples (1:100 in 1% bovine serum albumin in 1×PBS containing 0.1% Tween (PBST) were added to duplicate wells and incubated at 37°C for one hour. To each well, 100 μL of a 1:15000 dilution of goat anti-monkey IgG peroxidase-conjugated antibodies (Jackson ImmunoResearch, USA) was added wells and incubated at 37°C for one hour. The plates were washed 5 times with a wash buffer (1×PBST) post all incubations. One hundred microliters of (3,3’5,5’-Tetramethylbenzidine (TMB) substrate was added and incubated for 10 min. The reaction was stopped by 1N H2SO4 and absorbance was measured at 450 nm18. The sample was considered positive when the P/N ratio was more than 1.5. and optical density values with the SARS-CoV-2 antigen was above 0.2.

Plaque reduction neutralization test

The plaque reduction neutralization test (PRNT) was performed as described earlier²⁰. A four-fold serial dilution of rhesus macaque’s serum samples was mixed with an equal amount of virus suspension containing 50-60 plaque-forming units (PFU) in 0.1 ml. After incubating the mixtures at 37°C for 1 h, each virus-diluted serum sample (0.1 ml) was inoculated onto one well of a 24-well tissue culture plate containing a confluent monolayer of Vero CCL-81 cells. After incubating the plate at 37°C for 60 min, an overlay medium consisting of 2% carboxymethyl cellulose (CMC) with 2% fetal calf serum (FCS) in 2× MEM was added to the cell monolayer, and the plate was further incubated at 37°C in 5% CO₂ for 5 days. Plates were stained with 1% amido black for an hour. Antibody titers were defined as the highest serum dilution that resulted in >50 (PRNT50) reduction in the number of plaques.

Detection of SARS-CoV-2 genomic and subgenomic viral RNA

The organs harvested during necropsy were uniformly weighed and homogenized (Tissue homogenizer, Qiagen, Germany) using 1 ml of sterile MEM (GIBCO, Thermo Fisher Scientific, USA). Two hundred µl of each specimen (NS, TS, rectal swab, whole blood, BAL fluid, urine, CSF, and tissue homogenates) was used for RNA extraction using MagMAX™ Viral/Pathogen Nucleic Acid Isolation Kit (Thermo Fisher Scientific, USA). SARS-CoV-2 real-time RT-PCR was performed and a standard curve was plotted using in vitro transcribed RNA for E gene (gRNA) as described earlier^{21, 22}. Subgenomic RNA for the E gene was amplified using real-time RT-PCR from the above specimens using earlier published literature²³.

Lymphocyte subset and cytokine/chemokine profile

To analyze phenotype and proportion of T helper, T cytotoxic and B cells anti-coagulated (0.1ml) whole blood was surface-stained with appropriate fluorochrome-conjugated antibodies along with their corresponding isotype controls. Two sets of sample tubes were prepared, one for T cell (CD3-FITC, CD8-PE, CD4-APC) and another for B cell (CD45-PerCP, CD3-FITC, CD20-PE). After incubation for 30 min at 4⁰C in dark, 2 ml of RBC lysing buffer were added to each tube, vortexed, and incubated at room temperature for 12 min. Two milliliters of washing solution was added to each tube. The sample tubes were centrifuged at 200 x g for 5 min. and the supernatant was carefully aspirated out. The cell pellets were suspended in 500μl wash buffer and vortexed. Υ, α Υ,α

Virus isolation from clinical/necropsy specimens

One hundred microliters of each specimen were inoculated onto 24-well Vero CCL-81 cell monolayers maintained in MEM (Gibco, UK), and incubated for 1 h at 37°C with rocking every 10 min. Subsequently, the media was removed and cells were washed with 1× PBS. Media with 2% FBS was added to each well and was incubated in a CO₂incubator at 37°C for 5 days. The culture plate was examined daily for CPE using an inverted microscope (Nikon, Eclipse Ti, Japan)¹⁹. The cell culture supernatant from the wells showing CPE was further confirmed by real-time RT-PCR²¹.

Histopathological examination and Immunohistochemistry

Tissue sections from lungs were immersion-fixed in 10% neutral buffered formalin. Tissue processing and embedding were performed by techniques described earlier²⁵. Four micrometers thick tissue sections were used for hematoxylin and eosin staining. Anti-SARS-CoV-2 immunoreactivity in the tissues was assessed using mouse polyclonal serum. For IHC, mouse polyclonal serum was used as the primary antibody (1:500) and anti-mouse HRP antibody was used as a secondary antibody^{25, 17}.

Statistical analysis

Clinical, virological, hematological, biochemical, and immunological data were analyzed using GraphPad Prism software version 8.4.3 (GraphPad, San Diego, California) and Stata 14 software. (StataCorp LLC, USA). The clinical, virological, and serological data for the different groups were initially compared using the non-parametric Kruskal-Wallis test. The groups that were significant using the Kruskal-Wallis test were further assessed using the Mann-Whitney test. A group-wise comparison was performed to assess significance between the placebo and the other vaccinated groups using a two-tailed Mann-Whitney test. The p-values less than 0.05 were considered significant and are marked on the figures. Non-significant values are not depicted in the figures. The log10 plots below the detection limits are depicted as log10 (1) for the illustration purpose. The detection limits are marked with the dotted lines on the respective figures.

Reporting summary

The nature research reporting summary provided with this paper contains the information on research design.

Data availability

All the data other than those presented in the article are provided in the form of supplementary files.

There is NO Competing Interest.

Supplementarytable123.docx
Dataset 1, Dataset 2, Dataset 3. Supplementary Table 1: Clinical scoring sheet Supplementary Table 2: Histopathological scoring of lungs Supplementary Table 3: Daily observation parameters
ExtendedDataFigure1and2.pdf
Extended Data 1, Extended Data 2. Extended Data Figure. 1| Anteroposterior (AP) chest radiographs obtained from different animals. (A) Normal chest X-ray. (B) Infiltrate in left upper lobe (black arrowhead), bronchopneumonia in lower lobes of both the lungs (black circles). (C) Infiltrate in left upper lobe (white arrowhead) and lobar consolidation in left lower lobe (white arrow) (D) Lobar consolidation in left upper lobe (black arrow) with bilateral lower lobe bronchopneumonia (white circles) where ‘R’ represents the position indicator for the right side of the animal. Extended Data Figure. 2| Lymphocyte profile in animals of each group at 0,1,3,5 and 7 DPI. (A) Lymphocyte percentage. (B) Percentage of CD3+ T cells/lymphocytes. (C) Percentage of CD8+ T cells/ CD3+ T cells, (D) Percentage of CD4+ T cells/ CD3+ T cells. (E) Percentage of CD20+ T cells/ CD45+ cells.

PDF

Journal Publication

published 02 Mar, 2021

Read the published version in Nature Communications →

Version 1

posted 10 Sep, 2020

You are reading this latest preprint version

Remarkable immunogenicity and protective efficacy of BBV152, an inactivated SARS-CoV-2 vaccine in rhesus macaques

Status:

Journal Publication

Version 1

Abstract

Figures

Introduction

Results

Discussion

Declarations

References

Methods

Additional Declarations

Supplementary Files

Status:

Journal Publication

Version 1